BioPorto loses crucial patent trial
Years of judicial wrangling has come to an end for the Danish diagnostics company BioPorto, as the pivotal NGAL cut-off patent has been deemed invalid. The share drops by nearly 30% on the news.
by Benjamin Werner Christensen
The European Patent Office (EPO) has rejected BioPorto’s NGAL cut-off patent, because it is inadequately described, meaning the patent has been deemed invalid, the Danish company announced in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto in court settlement and Abbott-alliance
For abonnenter
BioPorto: Focus on sales pays off
For abonnenter
BioPorto: Postponement is very positive
For abonnenter
